Modern understanding of bronchial asthma with fixed airflow obstruction

Cover Page

Cite item

Full Text

Abstract

The review provides data on one of the phenotypes of severe bronchial asthma – it is asthma with fixed airway obstruction. According to data published today, there is no single pathway for the formation of fixed airway obstruction in patients with severe asthma. Increasing knowledge of the pathophysiology of fixed airway obstruction, as well as identifying the most significant risk factors, is essential for the successful treatment of such patients. In addition, the development of fixed obstruction is associated with a worse and sometimes fatal prognosis. Expanding the existing views is also necessary to overcome the difficulties of differential diagnosis between bronchial asthma with fixed airway obstruction and bronchial asthma in combination with COPD. All this will optimize the approach to the management of patients with bronchial asthma to prevent the formation of fixed airway obstruction.

About the authors

Angelina Yu. Kraposhina

Voino-Yasenetsky Krasnoyarsk State Medical University; Regional Clinical Hospital

Author for correspondence.
Email: angelina-maria@inbox.ru

к.м.н., доц. каф. внутренних болезней и иммунологии с курсом ПО ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого», врач-пульмонолог лечебно-диагностического отд-ния КГБУЗ ККБ

Russian Federation, Krasnoyarsk; Krasnoyarsk

Elena A. Sobko

Voino-Yasenetsky Krasnoyarsk State Medical University; Regional Clinical Hospital

Email: angelina-maria@inbox.ru
ORCID iD: 0000-0002-9377-5213

д.м.н., проф. каф. внутренних болезней и иммунологии с курсом ПО ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого», зав. отд-нием аллергологии КГБУЗ ККБ

Russian Federation, Krasnoyarsk; Krasnoyarsk

Irina V. Demko

Voino-Yasenetsky Krasnoyarsk State Medical University; Regional Clinical Hospital

Email: angelina-maria@inbox.ru
ORCID iD: 0000-0001-8982-5292

д.м.н., проф., зав. каф. внутренних болезней и иммунологии с курсом ПО ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого», зав. легочно-аллергологическим центром КГБУЗ ККБ

Russian Federation, Krasnoyarsk; Krasnoyarsk

Anna B. Kacer

Voino-Yasenetsky Krasnoyarsk State Medical University

Email: angelina-maria@inbox.ru
ORCID iD: 0000-0002-6649-8900

науч. сотр. каф. внутренних болезней и иммунологии с курсом ПО ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого»

Russian Federation, Krasnoyarsk

Olga V. Kazmerchuk

Voino-Yasenetsky Krasnoyarsk State Medical University

Email: angelina-maria@inbox.ru
ORCID iD: 0000-0001-7999-4113

науч. сотр. каф. внутренних болезней и иммунологии с курсом ПО ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого»

Russian Federation, Krasnoyarsk

Yuriy I. Abramov

Voino-Yasenetsky Krasnoyarsk State Medical University

Email: angelina-maria@inbox.ru
ORCID iD: 0000-0002-9937-1025

науч. сотр. каф. внутренних болезней и иммунологии с курсом ПО ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого»

Russian Federation, Krasnoyarsk

References

  1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2019 update). Available at: www.ginasthma.org. Accessed : 16.07.2019.
  2. Авдеев С.Н., Ненашева Н.М., Жуденков К.В., и др. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации. Пульмонология. 2018;28(3):341-58 [Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonology. 2018;28(3):341-58 (In Russ.)].doi: 10.18093/0869-0189-2018-28-3-341-358
  3. Konstantellou E, Papaioannou AI, Loukides S, et al. Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype. Respir Med. 2015;109:1404-9.doi: 10.1016/j.rmed.2015.09.009
  4. Ciebiada M, Domagała M, Gorska-Ciebiada M, Gorski P. Risk factors associated with irreversible airway obstruction in nonsmoking adult patients with severe asthma. Allergy Asthma Proc. 2014;35(5):72-9. doi: 10.2500/aap.2014.35.3785
  5. Bennett GH, Carpenter L, Hao W, et al. Risk factors and clinical outcomes associated with fixed airflow obstruction in older adults with asthma. Ann Allergy Asthma Immunol. 2018;120(2):164-8.doi: 10.1016/j.anai.2017.10.004
  6. Tashkin DP, Moore GE, Trudo F, et al. Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. J Allergy Clin Immunol Pract. 2016;4(4):705-12. doi: 10.1016/j.jaip.2016.02.014
  7. Haddad A, Gaudet M, Plesa M, et al. Neutrophils from severe asthmatic patients induce epithelial to mesenchymal transition in healthy bronchial epithelial cells. Respir Res. 2019;20(1):234.doi: 10.1186/s12931-019-1186-8
  8. Wang L, Gao S, Zhu W, Su J. Risk factors for persistent airflow limitation: analysis of 306 patients with asthma. Pak J Med Sci. 2014;30(6):1393-7. doi: 10.12669/pjms.306.5363
  9. Ten Brinke A, Zwinderman AH, Sterk PJ, et al. Persistent airflow limitation in asthma. Am J Respir Crit Care Med. 2001;164(5):744-8. doi: 10.1164/ajrccm.164.5.2011026
  10. Mogensen I, Alving K, Dahlen SE, et al. Fixed airflow obstruction relates to eosinophil activation in asthmatics. Clin Exp Allergy. 2019;49(2):155-62. doi: 10.1111/cea.13302
  11. Колобовникова Ю.В., Уразова О.И., Новицкий В.В. и др. Эозинофил: современный взгляд на кинетику, структуру и функцию. Гематология и трансфузиология. 2012;57(1):30-6 [Kolobovnikova YuV, Urazova OI, Novitsky VV, et al. Eosinophil: a modern concept of the kinetics, structure and function. Russian journal of hematology and transfusiology. 2012;57(1):30-6 (In Russ.)]
  12. Domingo C, Palomares O, Sandham DA, et al. The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation. Respir Res. 2018;19:189. doi: 10.1186/s12931-018-0893-x
  13. Takahashi K, Meguro K, Kawashima H, et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2019;56(3):236-43. doi: 10.1080/02770903.2018.1455855
  14. Shaw DE, Berry MA, Hargadon B, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007;132(6):1871-5. doi: 10.1378/chest.07-1047
  15. Pain M, Bermudez O, Lacoste P, et al. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014;23(131):118-30. doi: 10.1183/09059180.00004413
  16. Jarjour NN, Konno S. Mechanisms underlying fixed airflow obstruction and exacerbations. In: Chung KF, Israel E, Gibson PG, eds. Severe asthma. Sheffield, European Respiratory Society, 2019:82-92.
  17. Miravitlles M. Diagnosis of asthma–COPD overlap: the five commandments. Eur Respir J. 2017;49(5):1700506.doi: 10.1183/13993003.00506-2017
  18. Федосеев Г.Б., Трофимов В.И., Негруца К.В., и др. ACOS – самостоятельная нозологическая форма? Клиническая картина и диагностика ACOS. Пульмонология. 2018;28(5):519-29 [Fedoseev GB, Trofimov VI, Negrutsa KV, et al. Is ACOS an independent nosology? Clinical signs and diagnosis of ACOS. Russian Pulmonology. 2018;28(5):519-29 (In Russ.)]. doi: 10.18093/0869-0189-2018-28-5-519-529
  19. Chipps BE, Hirsch I, Trudo F, et al. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020;124(1):79-86.doi: 10.1016/j.anai.2019.10.006
  20. Oshita Y, Koga T, Kamimura T, et al. Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma. Thorax. 2003;58:757-60. doi: 10.1136/thorax.58.9.757
  21. Tonga KO, Chapman DG, Farah CS, et al. Reduced lung elastic recoil and fixed airflow obstruction in asthma. Respirology. 2019;1-7.doi: 10.1111/resp.13688
  22. Овсянников Н.В., Билевич О.А., Зинченко Л.М., Козлова Е.А. Новые возможности достижения контроля над течением тяжелой бронхиальной астмы. Вестн. современной клинической медицины. 2019;12(4):63-8 [Ovsyannikov NV, Bilevich OА, Zinchenko LM, Kozlova EA. New opportunities in achievement control over the course of severe bronchial asthma. Vestn. sovremennoi klinicheskoi mediciny. 2019;12(4):63-8 (In Russ.)]. doi: 10.20969/VSKM.2019.12(4).63-8
  23. Katoh S, Ikeda M, Shirai R, et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2018;55(10):1052-8. doi: 10.1080/02770903.2017.1391281
  24. Rawy AM, Mansour AI. Fraction of exhaled nitric oxide measurement as a biomarker in asthma and COPD compared with local and systemic inflammatory markers. Egypt J Chest Dis Tuberculosis. 2015;64:13-20. doi: 10.1016/j.ejcdt.2014.09.004
  25. Uzan GC, Borekci S, Doventas YE, et al. The relationship between inflammatory markers and spirometric parameters in ACOS, Asthma, and COPD. J Asthma. 2019;12:1-7. doi: 10.1080/02770903.2019.1652644
  26. Grzela K, Litwiniuk M, Zagorska W, Grzela T. Airway remodeling in chronic obstructive pulmonary disease and asthma: the role of matrix metalloproteinase-9. Arch Immunol Ther Exp. 2016;64(1):47-55.doi: 10.1007/s00005-015-0345-y
  27. Rogliani P, Ora J, Puxeddu E, Cazzola M. Airflow obstruction: is it asthma or is it COPD? Int J Chron Obstruct Pulmon Dis. 2016;11:3007-13. doi: 10.2147/COPD.S54927
  28. Kitaguchi Y, Yasuo M, Hanaoka M. Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation. Int J Chron Obstruct Pulmon Dis. 2016;11:991-7. doi: 10.2147/COPD.S105988
  29. Jones RL, Noble PB, Elliot JG, James AL. Airway remodelling in COPD: It’s not asthma! Respirology. 2016;21(8):1347-56.doi: 10.1111/resp.12841
  30. Ненашева Н.М. Терапия бронхиальной астмы, основанная на биомаркерах. Практическая пульмонология. 2018;4:3-11 [Nenasheva NM. Biomarker-based therapy of asthma. Prakticheskaya pul’monologiya. 2018;4:3-11 (In Russ.)].
  31. Воржева И.И., Хашкина Л.А. Роль омализумаба в лечении тяжелой терапевтически резистентой аллергической астмы с поражением мелких дыхательных путей и фиксированной бронхиальной обструкцией. Мед. совет. 2017;18:39-43. [Vorzheva II, Khashkina LA. Omalizumab rike in therapy of grave therapeutically resistent allergic asthma with involvement of small respiratory ways and fixed bronchial obstruction. a literature review and clinical observation. Med. sovet. 2017;18:39-43 (In Russ.)].doi: 10.21518/2079-701x-2017-18-39-43
  32. Демко И.В., Собко Е.А., Чубарова С.В., и др. Особенности системного воспаления, функции внешнего дыхания и морфологической структуры слизистой оболочки бронхов при тяжелой бронхиальной астме. Сиб. мед. обозрение. 2014;5:47-52 [Demko IV, Sobko EA, Chubarova SV, et al. Features of the systemic inflammation, external respiration functions and morphological structure of the bronchial mucous membrane in severe bronchial asthma. Siberian Medical Review. 2014;5:47-52 (In Russ.)]. doi: 10.20333/25000136-2014-5-47-52
  33. Gross NJ, Barnes PJ. New therapies for asthma and chronic obstructive pulmonary disease. Am J Respir Critical Care Med. 2017;195(2):159-66. doi: 10.1164/rccm.201610-2074PP

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies